Androgen receptor polymorphism dependent variation in prostate specific antigen concentrations of European men.
(2014) In Cancer Epidemiology Biomarkers & Prevention 23(10). p.2048-2056- Abstract
- Background Androgens acting via the androgen receptor (AR) stimulate production of prostate specific antigen (PSA), which is a clinical marker of prostate cancer (PCa). Since genetic variants in the AR may have a significant impact on the risk of being diagnosed with PCa, the aim was to investigate if AR-variants were associated with the risk of having PSA above clinically used cut-off thresholds of 3 or 4 ng/mL in men without PCa. Methods Men without PCa history (n=1744) were selected from the European Male Ageing Study (EMAS) cohort of 40-80 year old men from 8 different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR-variants (CAG repeat-length and/or SNP... (More)
- Background Androgens acting via the androgen receptor (AR) stimulate production of prostate specific antigen (PSA), which is a clinical marker of prostate cancer (PCa). Since genetic variants in the AR may have a significant impact on the risk of being diagnosed with PCa, the aim was to investigate if AR-variants were associated with the risk of having PSA above clinically used cut-off thresholds of 3 or 4 ng/mL in men without PCa. Methods Men without PCa history (n=1744) were selected from the European Male Ageing Study (EMAS) cohort of 40-80 year old men from 8 different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR-variants (CAG repeat-length and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cut-off concentrations for further investigation of PCa. Results Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95%CI 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG-repeats (median 20 vs. 23, p<0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion The A-allele of the SNP rs1204038 gives a 65% higher risk of having PSA above 3 ng/mL than the G-allele in men without PCa, and thereby an increased risk of being referred for further examination on suspicion of PCa. Impact Serum PSA as a clinical marker could be improved by adjustment for AR-genotype. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4583001
- author
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Epidemiology Biomarkers & Prevention
- volume
- 23
- issue
- 10
- pages
- 2048 - 2056
- publisher
- American Association for Cancer Research
- external identifiers
-
- pmid:25012998
- wos:000345277400011
- scopus:84907483721
- pmid:25012998
- ISSN
- 1538-7755
- DOI
- 10.1158/1055-9965.EPI-14-0376
- language
- English
- LU publication?
- yes
- id
- a2da45a7-23fa-45a9-ac0c-a9db2564fa30 (old id 4583001)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25012998?dopt=Abstract
- date added to LUP
- 2016-04-01 10:46:43
- date last changed
- 2022-04-11 12:19:33
@article{a2da45a7-23fa-45a9-ac0c-a9db2564fa30, abstract = {{Background Androgens acting via the androgen receptor (AR) stimulate production of prostate specific antigen (PSA), which is a clinical marker of prostate cancer (PCa). Since genetic variants in the AR may have a significant impact on the risk of being diagnosed with PCa, the aim was to investigate if AR-variants were associated with the risk of having PSA above clinically used cut-off thresholds of 3 or 4 ng/mL in men without PCa. Methods Men without PCa history (n=1744) were selected from the European Male Ageing Study (EMAS) cohort of 40-80 year old men from 8 different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR-variants (CAG repeat-length and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cut-off concentrations for further investigation of PCa. Results Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95%CI 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG-repeats (median 20 vs. 23, p<0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion The A-allele of the SNP rs1204038 gives a 65% higher risk of having PSA above 3 ng/mL than the G-allele in men without PCa, and thereby an increased risk of being referred for further examination on suspicion of PCa. Impact Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.}}, author = {{Bentmar Holgersson, Magdalena and Giwercman, Aleksander and Bjartell, Anders and Wu, Frederick C W and Huhtaniemi, Ilpo T and O'Neill, Terence W and Pendleton, Neil and Vanderschueren, Dirk and Lean, Michael E J and Han, Thang S and Finn, Joseph D and Kula, Krzysztof and Forti, Gianni and Casanueva, Felipe F and Bartfai, György and Punab, Margus and Giwercman, Yvonne}}, issn = {{1538-7755}}, language = {{eng}}, number = {{10}}, pages = {{2048--2056}}, publisher = {{American Association for Cancer Research}}, series = {{Cancer Epidemiology Biomarkers & Prevention}}, title = {{Androgen receptor polymorphism dependent variation in prostate specific antigen concentrations of European men.}}, url = {{http://dx.doi.org/10.1158/1055-9965.EPI-14-0376}}, doi = {{10.1158/1055-9965.EPI-14-0376}}, volume = {{23}}, year = {{2014}}, }